SCHEMBL5547486

SCHEMBL5547486

[CH2]c1csc2ccc(OC)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.47
MTNR1B P49286 4/20 0.47
MAPT P10636 5/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
TDP1 Q9NUW8 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BACE1 P56817 1/20 0.40
PSMB8 P28062 1/20 0.38
CDK1 P06493 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
HPGD P15428 1/20 0.37
CASP3 P42574 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542992 0.85 ALDH1A1 (0.42) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL5544022 0.81 ALDH1A1 (0.54) MTNR1AMAPTKDM4EALDH1A1TDP1
SCHEMBL23287803 0.79 MTNR1A (0.48) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL788146 0.79 CYP2A6 (0.56) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL5542588 0.77 GPR3 (0.42) MAPTKDM4ENPC1RAB9AHSD17B10
SCHEMBL17140096 0.75 MAPT (0.44) MAPTCA2
SCHEMBL6152697 0.74 CYP2A6 (0.58) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL6151456 0.74 MTNR1A (0.60) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL7340610 0.74 MTNR1A (0.57) MTNR1AMTNR1BMAPTKDM4EALDH1A1
SCHEMBL8555827 0.73 MTNR1A (0.56) MTNR1AMTNR1BMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MTNR1A 1560/4885MTNR1B 1562/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.